Synthesis of biocompatible iron oxide nanoparticles as a drug delivery vehicle

Int J Nanomedicine. 2018 Mar 15;13(T-NANO 2014 Abstracts):79-82. doi: 10.2147/IJN.S124708. eCollection 2018.


Over the last decade, there has been growing interest in developing novel nanoparticles (NPs) for biomedical applications. A safe-by-design approach was used in this study to synthesize biocompatible iron oxide NPs. The size of the particles obtained was ~100 nm. Although these NPs were significantly (P<0.05) internalized in MCF-7 (human breast adenocarcinoma cell line) cells, no adverse effect was observed in the cells as assessed by cytotoxicity assays (neutral red uptake and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) and cell cycle analysis. Our data demonstrate the potential of iron oxide NPs as a biocompatible carrier for targeted drug delivery.

Keywords: biocompatible iron oxide nanoparticles; coprecipitation; human breast adenocarcinoma cells.

MeSH terms

  • Cell Cycle / drug effects
  • Chemical Precipitation
  • Drug Carriers / adverse effects
  • Drug Carriers / chemistry
  • Drug Delivery Systems / methods*
  • Female
  • Ferric Compounds / adverse effects
  • Ferric Compounds / chemistry*
  • Humans
  • MCF-7 Cells
  • Nanoparticles / administration & dosage
  • Nanoparticles / adverse effects
  • Nanoparticles / chemistry*
  • Particle Size


  • Drug Carriers
  • Ferric Compounds
  • ferric oxide